Experience

Davis Polk advised the administrative agent, joint lead arranger and joint bookrunner in connection with a $925 million first-lien term loan facility and a $150 million asset-based…

Davis Polk advised Pernix Therapeutics Holdings, Inc. in connection with the sale of substantially all of its assets to Currax Holdings LLC, an entity formed by affiliates of Highbridge…

Davis Polk advised the administrative agent and the lenders in connection with the refinancing of Hologic, Inc.’s existing senior secured credit facilities with a $1.5 billion term loan…

Davis Polk is advising Nutrisystem, Inc. on its $1.4 billion acquisition by Tivity Health, Inc. The transaction, which is expected to close in the first quarter of 2019, is subject to…

Davis Polk advised Shire plc on concurrent tender offers by Baxalta Incorporated and Shire Acquisitions Investments Ireland DAC (“SAIIDAC”), both wholly owned subsidiaries of Shire,…

Davis Polk advised the representatives of the initial purchasers in connection with an unregistered offering of $20 billion in aggregate principal amount of senior notes by Halfmoon Parent,…

Davis Polk advised Pernix Therapeutics Holdings, Inc. in connection with separate private exchange offers for its existing 12% senior secured notes due 2020 held by certain holders for new…

Davis Polk advised Valeant Pharmaceuticals International, Inc. (“Valeant”) and Valeant Pharmaceuticals International in connection with a $4.565 billion senior secured term loan and $1.225…

Davis Polk advised the lenders in connection with a $3 billion 364-day term loan credit facility for AbbVie Inc.  Headquartered in Chicago, Illinois, AbbVie is a global research…

Davis Polk is advising Charles River Laboratories International, Inc. on its approximately $800 million acquisition of MPI Research Inc. The transaction, which is expected to close early in…